Developer docs
API playgroundTry for free, no card

Search company profiles

Nanowear

Full company profile

uuid0007mzr

Namestring
Nanowear
Legal namestring
Nanowear Inc.
Websiteurl
nanowearinc.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Nanowear Inc. is a New York-based healthcare technology company founded in 2014 that develops the FDA-cleared SimpleSense platform — a closed-loop AI diagnostic system built on proprietary cloth-based nanosensor technology. The platform's non-invasive, gender-neutral undergarment captures 85+ medical-grade biomarkers per millisecond directly from the skin, continuously recording cardiac, respiratory, vascular, and hemodynamic data. This physiological data feeds proprietary machine-learning algorithms trained on terabytes of unique human data, generating scored clinical-grade cardiometabolic assessments that replace up to eight conventional diagnostic tools. The company holds three FDA 510(k) clearances and is pursuing SOC 2 Type II certification alongside HIPAA compliance.

Nanowear serves enterprise healthcare buyers including clinical research organizations (CROs), pharmaceutical sponsors, cardiology practices, and hospital systems. Revenue is generated through subscription-based and managed-service contracts for clinical trial data services, cardiometabolic assessments, and hospital-at-home remote patient monitoring, with the platform used under the direction of licensed medical professionals. Recent strategic partnerships with Dexcom (March 2025) and Satio (April 2025) extend the platform into glucose monitoring and home-based drug delivery, targeting the $55 billion biopharma and $200 billion telehealth markets.

The company operates with a lean 1-10 employee team and remains private and venture-backed, with limited disclosed funding ($1.5 million seed in 2014). Its go-to-market combines direct enterprise sales to healthcare providers with channel partnerships for platform integrations and ecosystem expansion. Multiple industry awards (Frost & Sullivan, ACC, UCSF Digital Health, Philips Wearables Challenge) and CEO leadership roles at AdvaMed Accel provide external validation of its technology and positioning, though specific revenue scale and detailed ownership information remain undisclosed.

Short descriptiontext

Nanowear is a New York-based medical technology company that sells SimpleSense, an FDA-cleared AI diagnostic platform using patented cloth-based nanosensors to capture 85+ biomarkers from the skin for continuous cardiometabolic monitoring, serving CROs, pharmaceutical sponsors, cardiologists, and hospital systems.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote patient monitoring, wearable medical devices, cardiac diagnostics, nanosensor technology, clinical trial data services
Industry4 codes
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Remote Cardiac Monitoring
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Clinical Research Data Services
TypeSubscription Recurring
Description

Nanowear provides CROs and pharmaceutical sponsors with FDA-approved remote monitoring platforms for clinical trials, enabling patients to participate in studies from home, saving significant direct and indirect costs for research organizations.

nanowearinc.com
2Cardiometabolic Assessment Platform
TypeSubscription Recurring
Description

FDA-approved platform that provides cardiometabolic assessments to healthcare providers, digitally recording and transferring clinical grade diagnostics directly to patients' medical teams at the frequency of the prescribing cardiologist's direction.

nanowearinc.com
3Healthcare at Home Monitoring
TypeManaged Services
Description

Remote patient monitoring services enabling medical teams to view live clinical grade data on FDA-approved platform, providing continuous health monitoring from home with data streamed to healthcare providers.

nanowearinc.com
4Dexcom Integration Services
TypeProfessional Services
Description

Partnership with Dexcom to integrate glucose data into the wearable device for real-time comprehensive cardiometabolic health assessments for clinical research and patient care.

mobihealthnews.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Pricing details1 tier
1Enterprise healthcare provider pricing
ModelSubscriptionBilling cadenceMonthly
Notes

Pricing for healthcare institutions and cardiology practices is likely based on subscription or per-patient monitoring fees as the platform is used under physician direction with continuous data streaming.

nanowearinc.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1SimpleSense
Description

FDA-approved remote monitoring platform with AI diagnostics that captures 85+ medical grade biomarkers from cloth-based nanosensors worn as an undergarment, enabling full cardiometabolic assessment from home

nanowearinc.com
Core offering1 text field

Nanowear develops and sells the FDA-cleared SimpleSense platform, a remote monitoring and AI diagnostic system that combines a non-invasive cloth-based nanosensor undergarment with a cloud-based machine-learning platform and a patient-facing mobile app. The wearable captures 85+ medical-grade biomarkers per millisecond directly from the skin, and the AI platform produces closed-loop cardiometabolic assessments streamed to clinicians under physician direction. The offering is targeted at healthcare providers, cardiology practices, hospital systems, clinical research organizations, and pharmaceutical sponsors for clinical trials and remote patient monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 85+ medical grade biomarkers captured per millisecond
+2 more records
Product overview1 text field

Nanowear is a health technology company offering the SimpleSense platform — a unified FDA-cleared remote monitoring and AI diagnostic system. The platform consists of three integrated components: (1) the SimpleSense non-invasive undergarment (a cloth-based nanotechnology wearable), (2) the SimpleSense Platform (cloud-based software with closed-loop AI diagnostics), and (3) the SimpleSense App (patient-facing mobile interface). The wearable captures 85+ medical-grade biomarkers continuously from the skin, which are transmitted to the cloud platform where ML algorithms generate scored diagnostic data for clinicians. The system replaces up to eight diagnostic tools in a single platform, covering cardiac, respiratory, vascular, and hemodynamic monitoring for applications in clinical research, heart failure, structural cardiology, primary care, sleep apnea, and post-surgical recovery.

Product and service5 records
1SimpleSense Platform
CategoryRemote cardiac monitoring platform
Description

FDA-cleared remote monitoring and AI diagnostic platform that captures 85+ medical-grade biomarkers per millisecond via cloth-based nanotechnology and delivers closed-loop, clinical-grade cardiometabolic assessments to physicians and clinical research teams. Used under physician direction for clinical trials, remote patient monitoring, and hospital-at-home care.

2SimpleSense Non-Invasive Undergarment
CategoryWearable medical device
Description

One-size-fits-all, gender-neutral, non-invasive undergarment with proprietary cloth-based nanosensors that continuously collects heart rate, heart sounds, respiration rate via thoracic impedance, and physical activity/posture for cardiometabolic monitoring at home.

3SimpleSense App
CategoryPatient-facing mobile application
Description

Mobile application that allows users to document symptom-related information while wearing Nanowear remote monitoring devices, with data processed into clinical information communicated to the user's designated medical provider.

4Clinical Research Data Services
CategoryClinical trial data services
Description

Subscription-based service that provides CROs and pharmaceutical sponsors with FDA-approved remote monitoring for decentralized clinical trials, integrating each patient's metrics into one location, scored against a shared timeline, with no manual inputs or in-person visits.

5Cardiometabolic Assessment Service
CategoryCardiometabolic assessment service
Description

FDA-approved assessment service that captures the full symphony of a patient's heart, lungs, vascular, and hemodynamic systems continuously and time-synchronized, replacing up to eight diagnostic tools and digitally transferring clinical-grade diagnostics to the prescribing cardiologist's medical team.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-14
Description

Collaboration to develop advanced home-based diagnostic and therapeutic solutions integrating Nanowear's AI-based biomarker platform with Satio's blood draw and drug delivery patches. Partnership targets the $55 billion biopharma market and $200 billion telehealth segment, aiming to enhance remote healthcare by merging blood biomarkers with physiological data in a single digital platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-26
Description

Partnership to integrate glucose data from the Dexcom G7 system into Nanowear's wearable device, enabling real-time comprehensive cardiometabolic health assessments for clinical research and patient care. Collaboration expands Dexcom's diabetes management offerings and Nanowear's diagnostic capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Now part of Boston Scientific, Preventice offers BodyGuardian remote cardiac monitors for ambulatory ECG. Competes in the same hospital-and-cardiologist remote monitoring category as Nanowear's SimpleSense, with broader geographic and payer reach.

TypeEmerging player
Description

Remote patient monitoring platform focused on chronic-condition management including cardiovascular disease, sold to health systems and payers. Comparable to Nanowear's healthcare-at-home and cardiometabolic monitoring use cases but with a software-first model rather than a proprietary wearable.

TypeDirect peer
Description

Commercial-stage digital healthcare company focused on ambulatory cardiac monitoring (Zio patch), explicitly named as a competitor in the cardiovascular digital solutions market alongside Nanowear. Both companies sell FDA-cleared remote cardiac diagnostic platforms to clinicians, but iRhythm is single-modality while Nanowear positions as multi-biomarker.

TypeDirect peer
Description

Developer of KardiaMobile, an FDA-cleared single-lead ECG personal/device, and AI-enabled ECG analysis — overlapping with Nanowear's 2-lead ECG capture and AI diagnostic scoring for clinical and remote-monitoring use cases.

TypeEmerging player
Description

Leader in continuous glucose monitoring (G7) and a 2025 Nanowear integration partner. While not a direct cardiac competitor, Dexcom's data streams feed Nanowear's cardiometabolic platform, making it both an ecosystem ally and an adjacent wearable chronic-disease monitoring player.

TypeDirect peer
Description

Maker of digital stethoscopes with FDA-cleared AI cardiac and pulmonary disease detection, capturing heart sounds and ECG for clinician decision support — directly comparable to the cardiac, respiratory and AI-diagnostic elements of SimpleSense.

TypeBroad incumbent
Description

Explicitly cited by Nanowear's market context as a competitor in cardiovascular digital solutions. Apple Watch offers FDA-cleared ECG and irregular rhythm notifications, providing a consumer-grade alternative that competes for downstream physician attention and payer attention.

TypeEmerging player
Description

Consumer health wearables (ScanWatch, Body Cardio) with ECG and SpO2 capture. Partial overlap with Nanowear on the connected vital-signs wearable axis, primarily consumer rather than clinical-grade.

9VitalConnect
TypeDirect peer
Description

Provider of FDA-cleared wearable biosensor patches (Vista) for continuous remote cardiac and respiratory monitoring in hospital and home settings — directly comparable to SimpleSense's hospital-at-home and continuous cardiometabolic positioning.

TypeBroad incumbent
Description

Acquired by Philips, BioTelemetry provides ambulatory ECG and remote cardiac monitoring services at population scale. A broad incumbent in the same remote cardiac monitoring category Nanowear targets, with much larger sales coverage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nanowear

Remote Cardiac Monitoringnanowearinc.com

Nanowear is a New York-based medical technology company that sells SimpleSense, an FDA-cleared AI diagnostic platform using patented cloth-based nanosensors to capture 85+ biomarkers from the skin for continuous cardiometabolic monitoring, serving CROs, pharmaceutical sponsors, cardiologists, and hospital systems.

What Nanowear does

Nanowear Inc. is a New York-based healthcare technology company founded in 2014 that develops the FDA-cleared SimpleSense platform — a closed-loop AI diagnostic system built on proprietary cloth-based nanosensor technology. The platform's non-invasive, gender-neutral undergarment captures 85+ medical-grade biomarkers per millisecond directly from the skin, continuously recording cardiac, respiratory, vascular, and hemodynamic data. This physiological data feeds proprietary machine-learning algorithms trained on terabytes of unique human data, generating scored clinical-grade cardiometabolic assessments that replace up to eight conventional diagnostic tools. The company holds three FDA 510(k) clearances and is pursuing SOC 2 Type II certification alongside HIPAA compliance.

Nanowear serves enterprise healthcare buyers including clinical research organizations (CROs), pharmaceutical sponsors, cardiology practices, and hospital systems. Revenue is generated through subscription-based and managed-service contracts for clinical trial data services, cardiometabolic assessments, and hospital-at-home remote patient monitoring, with the platform used under the direction of licensed medical professionals. Recent strategic partnerships with Dexcom (March 2025) and Satio (April 2025) extend the platform into glucose monitoring and home-based drug delivery, targeting the $55 billion biopharma and $200 billion telehealth markets.

The company operates with a lean 1-10 employee team and remains private and venture-backed, with limited disclosed funding ($1.5 million seed in 2014). Its go-to-market combines direct enterprise sales to healthcare providers with channel partnerships for platform integrations and ecosystem expansion. Multiple industry awards (Frost & Sullivan, ACC, UCSF Digital Health, Philips Wearables Challenge) and CEO leadership roles at AdvaMed Accel provide external validation of its technology and positioning, though specific revenue scale and detailed ownership information remain undisclosed.

Nanowear firmographics

Firmographics
Name
Nanowear
Legal name
Nanowear Inc.
Website
https://nanowearinc.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Nanowear is a New York-based medical technology company that sells SimpleSense, an FDA-cleared AI diagnostic platform using patented cloth-based nanosensors to capture 85+ biomarkers from the skin for continuous cardiometabolic monitoring, serving CROs, pharmaceutical sponsors, cardiologists, and hospital systems.
Ownership category
akta.pro rank

Nanowear industry classification

Industry
Product category
Remote Cardiac Monitoring
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Remote patient monitoring
  • Wearable medical devices
  • Cardiac diagnostics
  • Nanosensor technology
  • Clinical trial data services

Where Nanowear is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nanowear business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Clinical Research Data Services: Nanowear provides CROs and pharmaceutical sponsors with FDA-approved remote monitoring platforms for clinical trials, enabling patients to participate in studies from home, saving significant direct and indirect costs for research organizations.
  2. Cardiometabolic Assessment Platform: FDA-approved platform that provides cardiometabolic assessments to healthcare providers, digitally recording and transferring clinical grade diagnostics directly to patients' medical teams at the frequency of the prescribing cardiologist's direction.
  3. Healthcare at Home Monitoring: Remote patient monitoring services enabling medical teams to view live clinical grade data on FDA-approved platform, providing continuous health monitoring from home with data streamed to healthcare providers.
  4. Dexcom Integration Services: Partnership with Dexcom to integrate glucose data into the wearable device for real-time comprehensive cardiometabolic health assessments for clinical research and patient care.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyEnterprise healthcare provider pricing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Nanowear product offering

Product offering

Core offering

Nanowear develops and sells the FDA-cleared SimpleSense platform, a remote monitoring and AI diagnostic system that combines a non-invasive cloth-based nanosensor undergarment with a cloud-based machine-learning platform and a patient-facing mobile app. The wearable captures 85+ medical-grade biomarkers per millisecond directly from the skin, and the AI platform produces closed-loop cardiometabolic assessments streamed to clinicians under physician direction. The offering is targeted at healthcare providers, cardiology practices, hospital systems, clinical research organizations, and pharmaceutical sponsors for clinical trials and remote patient monitoring.

Product overview

Nanowear is a health technology company offering the SimpleSense platform — a unified FDA-cleared remote monitoring and AI diagnostic system. The platform consists of three integrated components: (1) the SimpleSense non-invasive undergarment (a cloth-based nanotechnology wearable), (2) the SimpleSense Platform (cloud-based software with closed-loop AI diagnostics), and (3) the SimpleSense App (patient-facing mobile interface). The wearable captures 85+ medical-grade biomarkers continuously from the skin, which are transmitted to the cloud platform where ML algorithms generate scored diagnostic data for clinicians. The system replaces up to eight diagnostic tools in a single platform, covering cardiac, respiratory, vascular, and hemodynamic monitoring for applications in clinical research, heart failure, structural cardiology, primary care, sleep apnea, and post-surgical recovery.

Differentiator

Problem solved

Functional benefit

Brands

  • SimpleSense: FDA-approved remote monitoring platform with AI diagnostics that captures 85+ medical grade biomarkers from cloth-based nanosensors worn as an undergarment, enabling full cardiometabolic assessment from home

Products and services

  • SimpleSense Platform FDA-cleared remote monitoring and AI diagnostic platform that captures 85+ medical-grade biomarkers per millisecond via cloth-based nanotechnology and delivers closed-loop, clinical-grade cardiometabolic assessments to physicians and clinical research teams. Used under physician direction for clinical trials, remote patient monitoring, and hospital-at-home care.
  • SimpleSense Non-Invasive Undergarment One-size-fits-all, gender-neutral, non-invasive undergarment with proprietary cloth-based nanosensors that continuously collects heart rate, heart sounds, respiration rate via thoracic impedance, and physical activity/posture for cardiometabolic monitoring at home.
  • SimpleSense App Mobile application that allows users to document symptom-related information while wearing Nanowear remote monitoring devices, with data processed into clinical information communicated to the user's designated medical provider.
  • Clinical Research Data Services Subscription-based service that provides CROs and pharmaceutical sponsors with FDA-approved remote monitoring for decentralized clinical trials, integrating each patient's metrics into one location, scored against a shared timeline, with no manual inputs or in-person visits.
  • Cardiometabolic Assessment Service FDA-approved assessment service that captures the full symphony of a patient's heart, lungs, vascular, and hemodynamic systems continuously and time-synchronized, replacing up to eight diagnostic tools and digitally transferring clinical-grade diagnostics to the prescribing cardiologist's medical team.

Quantifiable outcome

  • 85+ medical grade biomarkers captured per millisecond
  • +2 more outcomes

Companies that use Nanowear

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Nanowear technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

Nanowear partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SatiocoreStrategic or Co-development Partner · 14 April 2025Collaboration to develop advanced home-based diagnostic and therapeutic solutions integrating Nanowear's AI-based biomarker platform with Satio's blood draw and drug delivery patches. Partnership targets the $55 billion biopharma market and $200 billion telehealth segment, aiming to enhance remote healthcare by merging blood biomarkers with physiological data in a single digital platform.
  • DexcomcoreTechnology or Integration · 26 March 2025Partnership to integrate glucose data from the Dexcom G7 system into Nanowear's wearable device, enabling real-time comprehensive cardiometabolic health assessments for clinical research and patient care. Collaboration expands Dexcom's diabetes management offerings and Nanowear's diagnostic capabilities.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Nanowear competitors and assessment

Company assessment

Broad incumbents

  • Preventice Solutions (Boston Scientific): Now part of Boston Scientific, Preventice offers BodyGuardian remote cardiac monitors for ambulatory ECG. Competes in the same hospital-and-cardiologist remote monitoring category as Nanowear's SimpleSense, with broader geographic and payer reach.
  • Apple: Explicitly cited by Nanowear's market context as a competitor in cardiovascular digital solutions. Apple Watch offers FDA-cleared ECG and irregular rhythm notifications, providing a consumer-grade alternative that competes for downstream physician attention and payer attention.
  • BioTelemetry (Philips): Acquired by Philips, BioTelemetry provides ambulatory ECG and remote cardiac monitoring services at population scale. A broad incumbent in the same remote cardiac monitoring category Nanowear targets, with much larger sales coverage.

Emerging players

  • Vivify Health: Remote patient monitoring platform focused on chronic-condition management including cardiovascular disease, sold to health systems and payers. Comparable to Nanowear's healthcare-at-home and cardiometabolic monitoring use cases but with a software-first model rather than a proprietary wearable.
  • Dexcom: Leader in continuous glucose monitoring (G7) and a 2025 Nanowear integration partner. While not a direct cardiac competitor, Dexcom's data streams feed Nanowear's cardiometabolic platform, making it both an ecosystem ally and an adjacent wearable chronic-disease monitoring player.
  • Withings: Consumer health wearables (ScanWatch, Body Cardio) with ECG and SpO2 capture. Partial overlap with Nanowear on the connected vital-signs wearable axis, primarily consumer rather than clinical-grade.

Direct peers

  • iRhythm Technologies: Commercial-stage digital healthcare company focused on ambulatory cardiac monitoring (Zio patch), explicitly named as a competitor in the cardiovascular digital solutions market alongside Nanowear. Both companies sell FDA-cleared remote cardiac diagnostic platforms to clinicians, but iRhythm is single-modality while Nanowear positions as multi-biomarker.
  • AliveCor: Developer of KardiaMobile, an FDA-cleared single-lead ECG personal/device, and AI-enabled ECG analysis — overlapping with Nanowear's 2-lead ECG capture and AI diagnostic scoring for clinical and remote-monitoring use cases.
  • Eko Health: Maker of digital stethoscopes with FDA-cleared AI cardiac and pulmonary disease detection, capturing heart sounds and ECG for clinician decision support — directly comparable to the cardiac, respiratory and AI-diagnostic elements of SimpleSense.
  • VitalConnect: Provider of FDA-cleared wearable biosensor patches (Vista) for continuous remote cardiac and respiratory monitoring in hospital and home settings — directly comparable to SimpleSense's hospital-at-home and continuous cardiometabolic positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Nanowear social profiles

Digital presence

Nanowear compliance and trust

Trust signal

Compliance3 records

Nanowear financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanowear leadership team

Management profile

Number of profiles

Profiles2 records

Nanowear funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanowear M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanowear

What does Nanowear do?

Nanowear develops and sells the FDA-cleared SimpleSense platform, a remote monitoring and AI diagnostic system that combines a non-invasive cloth-based nanosensor undergarment with a cloud-based machine-learning platform and a patient-facing mobile app. The wearable captures 85+ medical-grade biomarkers per millisecond directly from the skin, and the AI platform produces closed-loop cardiometabolic assessments streamed to clinicians under physician direction. The offering is targeted at healthcare providers, cardiology practices, hospital systems, clinical research organizations, and pharmaceutical sponsors for clinical trials and remote patient monitoring.

Is Nanowear a public or private company?

Nanowear is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nanowear founded?

Nanowear was founded in 2014. It employs 11 to 50 people.

Where is Nanowear based?

Nanowear is headquartered in New York, United States, in the North America region.

How does Nanowear make money?

Four revenue lines are on record. Clinical Research Data Services are the primary driver. The others are cardiometabolic Assessment Platform, healthcare at Home Monitoring and dexcom Integration Services.

Who are Nanowear's main competitors?

Broad incumbents on record are Preventice Solutions (Boston Scientific), Apple and BioTelemetry (Philips). Emerging players are Vivify Health, Dexcom and Withings. Direct peers are iRhythm Technologies, AliveCor, Eko Health and VitalConnect.

Does Nanowear have an API?

No public API is recorded for Nanowear.

What industry is Nanowear in?

Nanowear's product category is Remote Cardiac Monitoring. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comLeading Companies Reinforcing Their Presence in the Remote Blood-Draw Dried-Spot Device MarketThe remote blood-draw dried-spot device market is projected to grow to $1.73 billion by 2030 at a CAGR of 13.2%, driven by home healthcare adoption, chronic disease monitoring, and decentralized diagnostic testing. In April 2025, Boston, a US biotechnology firm, partnered with Nanowear Inc. to develop wearable biosensors combining AI-driven nanotechnology with blood testing and drug delivery. In March 2025, Tasso Inc. launched an advanced dried blood spot collection technology for clinical trials and sports anti-doping applications.MeditechinsightsBlood Pressure Monitoring Devices Market Size & Growth Report 2030The global blood pressure monitoring devices market is projected to grow at a compound annual growth rate of approximately 9% through 2030, driven by rising hypertension prevalence, sedentary lifestyles, and technological advancements in wearable and cuffless monitoring devices. Key developments include Health Canada's approval of the Aktiia Bracelet (November 2024), Novosound's introduction of the first ultrasonic cuffless blood pressure monitor (October 2024), and Nanowear's FDA clearance for its AI-enabled SimpleSense-BP wearable undergarment (January 2024). Regulatory and compliance challenges, along with accuracy concerns in wearable devices, remain restraints on market growth.AdvamedSatio, Nanowear announce partnership offering first, holistic, home-based in vivo- + in vitro diagnostics + drug deliverySatio and Nanowear have announced a partnership to combine their respective home-based diagnostic and drug delivery technologies into a holistic platform for precision therapeutics. This collaboration integrates Nanowear’s AI-based nanotechnology biomarker diagnostics with Satio’s blood draw systems and patches, targeting the biopharma and clinical research markets.SatiopatchCutting Edge At-Home MedTech and Digital Health Companies, Satio and Nanowear, to Collaborate on Accelerating Non-invasive Biomarkers, Diagnostics and Drug Delivery, Beyond the Remote Monitoring and DSatio and Nanowear announced a collaboration to advance home-based diagnostic and therapeutic care, integrating Nanowear’s AI biomarker platform with Satio’s blood draw and drug delivery patches. The partnership aims to merge blood and physiological data within a single platform to enable early diagnosis and personalized medicine, targeting a market valued at approximately $55 billion.PR NewswireCutting Edge At-Home MedTech and Digital Health Companies, Satio and Nanowear, to Collaborate on Accelerating Non-invasive Biomarkers, Diagnostics and Drug Delivery, Beyond the Remote Monitoring and DSatio and Nanowear announced a partnership to combine Nanowear's SimpleSense AI-based cardiometabolic diagnostics with Satio's blood draw and drug delivery patches. The collaboration aims to integrate in vitro and in vivo biomarkers for precision therapeutics, targeting a $55 billion biopharma market and a $200 billion home-based care market.TradingViewDXCM Inks Deal With Nanowear to Boost CGM Application Beyond DiabetesDexCom signed a licensing and data partnership with Nanowear to use G7 CGM data alongside cardiovascular biomarkers for investigational purposes. The collaboration creates a self-administered cardiometabolic assessment tool, expanding CGM beyond diabetes. DexCom faces competition from Abbott's FreeStyle Libre, with its 15-day sensor approval delayed by FDA warnings.MobiHealthNewsNanowear announces partnership with DexcomNanowear announced a licensing and data partnership with Dexcom to integrate Dexcom G7 glucose data into its SimpleSense wearable. The integration will combine glucose readings with cardiovascular biomarkers for real-time cardiometabolic assessments. The company says this enables precision medicine and individualized care.TmcnetNanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomNanowear announced a licensing and data partnership with Dexcom to ingest glucose data from Dexcom G7 CGM systems into its SimpleSense platform. The integration adds continuous glucose readings to its existing cardiometabolic biomarkers, offering real-time cardiometabolic assessments for clinical research. The company plans to present the integration at ACC Scientific Sessions 2025.YahooNanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomNanowear announced a partnership to ingest Dexcom G7 CGM data into its SimpleSense platform, enabling home-based cardiometabolic assessments. The integration adds glucose readings to existing cardiovascular biomarkers, offering time-synchronous diagnostics for research communities. The company states this is the first-and-only self-administered assessment of 9 combinatorial tools.YahooNanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomNanowear announced a data partnership with Dexcom to ingest G7 CGM data into its SimpleSense platform, enabling home-based cardiometabolic assessments. The integration adds glucose readings to existing cardiovascular biomarkers, offering real-time diagnostic data for clinical research. The company stated this is the first-in-the-world self-administered assessment of nine time-synchronous diagnostic tools.